WILMINGTON, Mass., April 4 /PRNewswire-FirstCall/ -- CardioTech International, Inc. , a leader in materials science technology, medical device engineering services and contract manufacturing, today launched a new website www.cardiotech-inc.com. The new website provides easy access to CardioTech’s broad array of polymer technology, products and medical device contract development and manufacturing services to showcase the Company’s unique position in the marketplace.
(Logo: http://www.newscom.com/cgi-bin/prnh/20070322/CLTH022LOGO)
Commenting on today’s announcement, Andrew M. Reed, Ph.D., CardioTech’s Vice President of Science and Technology said, “Our unique materials science strengths, embodied in our ChronoFlex(R) proprietary polymers, leverage our core technology and have the potential to be marketed beyond our existing customer base to a broader range of medical device companies. We believe we have an opportunity to fill a void that exists in the marketplace with our strong materials science capabilities to maximize the early development phase of devices that utilize polymers. Our new website is designed to enable senior engineers and directors of engineering at medical companies to efficiently locate and review our products and services they need to bring their medical devices to the next level or to perform in a novel manner.”
CardioTech’s products and services address medical device sectors and related products, including:
-- Orthopedics - artificial joints -- Spine - spinal implants -- Drug delivery - oncology ports and catheters -- Cardiovascular - stents, stent coatings -- Endoscopy - biliary stents -- Diagnostic sensors - blood glucose, blood gas analyzers -- Urology - catheters and catheter coatings -- Neurology - thrombectomy catheter -- Gastroenterology - feeding tubes -- Short and long-term implantable devices -- Ear/Nose/Throat - Inner ear drug delivery catheters -- Interventional radiology - peripheral balloons, infusion catheters.
Garryl Hudgins, Ph.D., CardioTech’s Project Development Engineering Director, noted that “Our new website provides in-depth information in one location for a broad range of medical device companies whose size spans from multinational firms to seed ventures. Our goal is to deliver better product designs to our customers by combining our advanced polymer technologies with new product applications. We have recently sharpened our focus and begun to truly integrate our materials science technology with our engineering and contract manufacturing.”
About CardioTech International:
CardioTech International, Inc. is a leader in materials science technology, medical device engineering services and contract manufacturing. The Company designs, develops, manufactures and sells innovative products and materials for the treatment of cardiovascular, orthopedic, oncology, urology and other diseases. CardioTech generates revenues from sales of advanced medical devices and materials, as well as from contracted product design and development services. A European clinical trial has recently begun for CardioPass(TM), CardioTech’s proprietary, synthetic coronary artery bypass graft. (SynCAB). The Company’s mission is to be a world class technology company focused on customer-driven solutions in the medical device industry. More information about CardioTech is available at its website: http://www.cardiotech-inc.com. To sign up for future e-mail alerts from CardioTech, press Investors on the website.
CardioTech International believes that this press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to risks and uncertainties. Such statements are based on management’s current expectations and are subject to facts that could cause results to differ materially from the forward-looking statements. For further information you are encouraged to review CardioTech’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the period ended March 31, 2006 and its Quarterly Reports on Form 10-Q for the periods ended June 30, 2006, September 30, 2006 and December 31, 2006. The Company assumes no obligation to update the information contained in this press release.
For Further Information Contact: Andrew M. Reed, Ph.D. Vice President of Science & Technology 978-657-0075 Garryl Hudgins, Ph.D. Project Development Engineering Director 763-225-8248 Resource Center for Business Development Products and Services: 866 469 0075 Investors/Press: Sylvia Dresner Senior Vice President VMW Corporate & Investor Relations 212-616-6161 info@vmwcom
Photo: http://www.newscom.com/cgi-bin/prnh/20070322/CLTH022LOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comCardioTech International, Inc.
CONTACT: Andrew M. Reed, Ph.D., Vice President of Science & Technology,+1-978-657-0075, Garryl Hudgins, Ph.D., Project Development EngineeringDirector, +1-763-225-8248; Investors-Press, Sylvia Dresner, Senior VicePresident, VMW Corporate & Investor Relations, +1-212-616-6161, info@vmwcom
Web site: http://www.cardiotech-inc.com//
